Stay updated on Risankizumab in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Risankizumab in Psoriatic Arthritis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedAdded '2023 ( U.S. NIH Grant/Contract )' to the study identifiers. Updated the page revision from v3.6.5 to v3.6.6.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe revision label changed from v3.6.4 to v3.6.5 on the page, indicating a small update to the page’s version. It does not alter the study details or user-facing functionality.SummaryDifference0.0%

- Check51 days agoChange DetectedThe study record status changed from Active, not recruiting to Completed, indicating that participant enrollment has ended. This update also notes a new last update date (2026-07-20) and a revision bump to v3.6.4.SummaryDifference0.2%

- Check73 days agoChange DetectedRevision: v3.6.3 is now displayed, replacing Revision: v3.6.2. This appears to be a versioning/template update rather than a change to page content or user-facing information.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page revision identifier has been updated from v3.6.0 to v3.6.2, signaling a newer version of the page's metadata. This change reflects a behind-the-scenes update and does not modify the main content visible to users.SummaryDifference0.0%

- Check94 days agoChange DetectedNew reader guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention label formatting changed from 'Intervention / Treatment' to 'Intervention/Treatment'. A recruitment-status note ('No longer looking for participants') was added and the page revision indicator updated to 'Revision: v3.6.0'.SummaryDifference0.2%

Stay in the know with updates to Risankizumab in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in Psoriatic Arthritis Clinical Trial page.